Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $16.07 Average Price Target from Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $13.79.

A number of research firms recently commented on MRNS. Robert W. Baird reaffirmed a “neutral” rating on shares of Marinus Pharmaceuticals in a research note on Tuesday, April 16th. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 price target (down from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday, April 15th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price objective on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. Finally, HC Wainwright decreased their price target on Marinus Pharmaceuticals from $27.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday.

Marinus Pharmaceuticals Stock Up 6.1 %

Marinus Pharmaceuticals stock opened at $1.57 on Friday. The company’s 50-day moving average price is $6.35 and its two-hundred day moving average price is $7.89. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The stock has a market cap of $86.24 million, a price-to-earnings ratio of -0.60 and a beta of 1.14. Marinus Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $11.26.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. During the same period in the prior year, the company earned ($0.76) earnings per share. On average, analysts expect that Marinus Pharmaceuticals will post -2.23 EPS for the current fiscal year.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MRNS. Eventide Asset Management LLC boosted its position in shares of Marinus Pharmaceuticals by 42.8% during the third quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company’s stock worth $36,466,000 after purchasing an additional 1,356,800 shares in the last quarter. Jennison Associates LLC boosted its position in Marinus Pharmaceuticals by 58.4% during the third quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock worth $23,791,000 after purchasing an additional 1,089,913 shares during the period. abrdn plc bought a new position in Marinus Pharmaceuticals in the 4th quarter valued at about $6,006,000. Superstring Capital Management LP bought a new stake in Marinus Pharmaceuticals in the 4th quarter valued at $5,027,000. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Marinus Pharmaceuticals by 6.3% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock valued at $23,381,000 after purchasing an additional 173,226 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.